MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine–Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective
The DOI matches its Crossref record; 229 of the 231 references it cites were found in a registry or an index.
Abstract
Despite dopamine-glutamate aberrant interaction that has long been considered a relevant landmark of psychosis pathophysiology, several aspects of these two neurotransmitters reciprocal interaction remain to be defined. The emerging role of postsynaptic density (PSD) proteins at glutamate synapse as a molecular "lego" making a functional hub where different signals converge may add a new piece of information to understand how dopamine-glutamate interaction may work with regard to schizophrenia pathophysiology and treatment. More recently, compelling evidence suggests a relevant role for microRNA (miRNA) as a new class of dopamine and glutamate modulators with regulatory functions in the reciprocal interaction of these two neurotransmitters. Here, we aimed at addressing the following issues: (i) Do miRNAs have a role in schizophrenia pathophysiology in the context of dopamine-glutamate aberrant interaction? (ii) If miRNAs are relevant for dopamine-glutamate interaction, at what level this modulation takes place? (iii) Finally, will this knowledge open the door to innovative diagnostic and therapeutic tools? The biogenesis of miRNAs and their role in synaptic plasticity with relevance to schizophrenia will be considered in the context of dopamine-glutamate interaction, with special focus on miRNA interaction with PSD elements. From this framework, implications both for biomarkers identification and potential innovative interventions will be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the glutamate is a major tonic/phasic release regulator or serotonin, dopamine, and norepinephrine, meaning that the phenomenon of pharmacodynamic tolerance takes more than a handful of monoamine, and/or multiple sites, timing and regulators [42].”
Citations
Cites
Items 201–229 of 229
Lugli, G., Larson, J., Demars, M. P., & Smalheiser, N. R. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07921.x · Cited by 41
Iasevoli, F., Polese, D., Ambesi-Impiombato, A., Muscettola, G., & de Bartolomeis, A. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.041 · Cited by 40
Self-citationde Bartolomeis, A., Marmo, F., Buonaguro, E. F., Rossi, R., Tomasetti, C., & Iasevoli, F. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.11.014 · Cited by 39
Self-citationRizig, M. A., McQuillin, A., Ng, A., Robinson, M., Harrison, A., Zvelebil, M., Hunt, S. P., & Gurling, H. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112450780 · Cited by 39
Jentsch, J. D., Wise, A., Katz, Z., & Roth, R. H. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199801)28:1<21::aid-syn3>3.0.co;2-e · Cited by 39
Ambesi‐Impiombato, A., Panariello, F., Dell'aversano, C., Tomasetti, C., Muscettola, G., & de Bartolomeis, A. (2007) · Synapse · doi:10.1002/syn.20385 · Cited by 38
Self-citationHa, C. M., Park, D., Han, J.-K., Jang, J.-I., Park, J., Hwang, E. M., Seok, H., & Chang, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.370601 · Cited by 37
MicroRNA 142-3p Mediates Post-Transcriptional Regulation of D1 Dopamine Receptor Expression
Tobón, K. E., Chang, D., & Kuzhikandathil, E. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049288 · Cited by 36
Sun, P., Wang, J., Gu, W., Cheng, W., Jin, G.-Z., Friedman, E., Zheng, J., & Zhen, X. (2009) · Cell Research · doi:10.1038/cr.2009.30 · Cited by 35
Lost in translation. New unexplored avenues for neuropsychopharmacology: epigenetics and microRNAs
Tardito, D., Mallei, A., & Popoli, M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.749237 · Cited by 35
Recent evidence for dopamine abnormalities in schizophrenia
Abi-Dargham, A. (2002) · European Psychiatry · doi:10.1016/s0924-9338(03)00075-0 · Cited by 34
Klugmann, M., & Szumlinski, K. K. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830c369f · Cited by 33
Group I Metabotropic Glutamate Receptor-mediated Gene Expression in Striatal Neurons
Mao, L., Zhang, G.-C., Liu, X., Fibuch, E. E., & Wang, J. Q. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9654-4 · Cited by 31
Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of δ-opioid receptor
Olianas, M. C., Dedoni, S., & Onali, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.012 · Cited by 29
Pedersen, C. S., Goetghebeur, P., & Dias, R. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.09.014 · Cited by 28
Marquis, J., Audet, M., Doré, F. Y., & Goulet, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.017 · Cited by 24
Therapeutic Evaluation of microRNAs by Molecular Imaging
Sekar, T. V., Ramkumar, K. M., Foygel, K., & Paulmurugan, R. (2013) · Theranostics · doi:10.7150/thno.4928 · Cited by 24
Qi, Z., Kikuchi, S., Tretter, F., & Voit, E. O. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1273707 · Cited by 23
Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia
Reid, M. A., Kraguljac, N. V., Avsar, K. B., White, D. M., den Hollander, J. A., & Lahti, A. C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.036 · Cited by 23
Sutton, L. P., & Rushlow, W. J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07268.x · Cited by 22
MicroRNAs - A New Generation Molecular Targets for Treating Cellular Diseases
Paulmurugan, R. (2013) · Theranostics · doi:10.7150/thno.8113 · Cited by 22
Can MicroRNAs Improve the Management of Lung Cancer Patients? A Clinician's Perspective
Tufman, A., Tian, F., & Huber, R. M. (2013) · Theranostics · doi:10.7150/thno.6615 · Cited by 21
de Bartolomeis, A., Avvisati, L., Iasevoli, F., & Tomasetti, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.034 · Cited by 18
Self-citationYang, L., Hong, Q., Zhang, M., Liu, X., Xiao-qin, P., Guo, M., Li, F., Guo, X., Tong, M., & Chi, X. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.030 · Cited by 17
Protein–protein interactions as therapeutic targets in neuropsychopharmacology
Reilly, M. T., Cunningham, K. A., & Natarajan, A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.167 · Cited by 16
Vargas, G. A. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.138 · Cited by 16
Identification of Developmentally Regulated PCP-Responsive Non-Coding RNA, prt6, in the Rat Thalamus
Takebayashi, H., Yamamoto, N., Umino, A., & Nishikawa, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097955 · Cited by 9
Nucleus Accumbens Homer Proteins Regulate Behavioral Sensitization to Cocaine
Ghasemzadeh, M. B., Permenter, L. K., LAKE, R. W., & Kalivas, P. W. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.034 · Cited by 8
Altered gene expression and neuropathology in Alzheimer's disease
Brasnjevic, I., Steinbusch, H. W. M., & Schmitz, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.029 · Cited by 2
Research works printed but not linked: 1
- de Bartolomeis A, Latte G, Tomasetti C, Iasevoli F (2014) Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol Neurobiol 49(1):484–511. doi: 10.1007/s12035-013-8534-3 · DOI
Cited by
de Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccarelli, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02976-3 · Cited by 113
Self-citationFornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
Dysregulation of mi RNA and its potential therapeutic application in schizophrenia
Cao, T., & Zhen, X. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12840 · Cited by 77
Tomasetti, C., Iasevoli, F., Buonaguro, E., De Berardis, D., Fornaro, M., Fiengo, A., Martinotti, G., Orsolini, L., Valchera, A., Di Giannantonio, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010135 · Cited by 71
“Moreover, a crucial role of microRNAs interactions with PSD molecules has been suggested in the radical synaptic plasticity rearrangements induced by antipsychotics [66].”
BackgroundSelf-citationNarla, S. T., Lee, Y. W., Benson, C. A., Sarder, P., Brennand, K., Stachowiak, E. K., & Stachowiak, M. K. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.12.012 · Cited by 64
“Earlier studies have shown that somemiRNAs may be dysregulated in the brains of schizophrenia patients (de Bartolomeis et al., 2015; Hill et al., 2014).”
Background
Metadata
- Authors
- de Bartolomeis, A., Iasevoli, F., Tomasetti, C., & Buonaguro, E. F.
- Affiliations
- Federico II University Hospital (IT)
- Venue
- Molecular Neurobiology
- Published
- 2014-11-14
- Volume
- 52
- Issue
- 3
- Pages
- 1771-1790
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2062239841
- Cited by
- 21
- References
- 231
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 3
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- microRNA, schizophrenia, dopamine-glutamate interaction, postsynaptic density, synaptic plasticity, microRNA biogenesis, antipsychotic drugs, theranostics, biomarkers, glutamatergic synapses
- MeSH terms
- Animals, Dopamine, Humans, Neuronal Plasticity, Schizophrenia, Antipsychotic Agents, Glutamic Acid, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.